What happened with GRAL today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
GRAIL’s Galleri test looks for cancer signals in blood and identifies the organ or tissue they likely came from by analyzing chemical patterns on DNA released by tumors. The company processes commercial tests at its Durham, North Carolina laboratory. Galleri is a screening test, not a cancer diagnosis: a positive result needs diagnostic follow-up, and a negative result does not rule out cancer. Most revenue comes from U.S. test sales, with patients paying out of pocket or testing funded by participating employers and other payors. Healthcare providers and commercial partners help bring in orders.
Galleri lacks broad insurance reimbursement, including broad Medicare coverage, so demand depends on whether patients, providers and payors see enough clinical and economic value in testing. It is currently sold as a laboratory-developed test without FDA approval or clearance. GRAIL has applied for FDA approval and plans to seek broad reimbursement if approval is obtained. Its NHS-Galleri Trial did not meet its main goal of reducing combined late-stage cancer diagnoses, an outcome relevant to decisions about adoption and coverage.
GRAIL also earns a smaller stream of revenue from research services for biopharmaceutical and clinical customers. Its research-use-only precision-oncology offering supports biomarker testing and clinical studies; this revenue depends heavily on partners continuing their trials. Commercial testing also relies on Illumina as the sole supplier of sequencing equipment, associated reagents and servicing.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
GRAIL’s results hinge on Galleri adoption, clinical evidence and reimbursement; watch Exact Sciences, a direct multi-cancer early detection rival missing from this list.
Guardant Health competes with GRAIL for blood-based early cancer screening and for testing work from cancer-care and biopharmaceutical customers. Its Shield screening revenue and biopharma testing business are the lines to watch for competition with Galleri and GRAIL’s research services.
GRAIL depends on Illumina for DNA-reading instruments and certain lab reagents, and owes it a perpetual royalty on qualifying oncology revenue. GRAIL expects a 7% rate when the suspension ends on December 24, 2026, or earlier upon a change of control, partly offsetting the margin benefits of higher testing volume.
Natera competes with GRAIL for cancer-monitoring and biopharmaceutical research testing, selling personalized blood tests and offering Signatera to cancer researchers and drug companies. Its announced multi-cancer early detection plans could also bring it into competition with Galleri, making progress toward a launch worth watching.
GRAIL depends on Twist Bioscience Corporation as its sole supplier of the DNA panels used in its cancer-testing lab workflows. Twist manufactures synthetic DNA; news about the supply or quality of those panels matters to GRAIL’s ability to keep testing running.
Caris Life Sciences, Inc. competes for oncology research customers served by GRAIL, selling tumor and blood profiling and research services to physicians, researchers and biopharmaceutical companies. Its multi-cancer early detection products in development would also compete with Galleri, so their development progress matters beyond today’s research business.
AstraZeneca uses GRAIL’s tests and methylation technology in cancer-drug trials and in developing tests to help identify patients for treatment, so its trial decisions can affect GRAIL’s research revenue and development opportunities. In late 2025, AstraZeneca ended the phase 3 TROPION-Lung12 trial for low enrollment; GRAIL’s technology had been used as a potential companion diagnostic to enroll participants.
Personalis, Inc. and GRAIL compete for drug companies’ cancer-monitoring and biomarker research work. Personalis sells cancer genetic testing that supports therapy development and clinical trials, making its biopharmaceutical research business more relevant to GRAIL than its whole-genome sequencing projects.
Tempus AI competes with GRAIL for precision-oncology testing and clinical-study work paid for by life sciences companies. Alongside its lab tests, Tempus offers clinical-trial support through Trials; that work is the relevant overlap with GRAIL’s development services.
Illumina Inc earningsILMN
Illumina's report can flag conditions in the sequencing-instrument and reagent businesses that supply key inputs to GRAIL's lab.
Watch for Illumina's disclosures about its sequencing instruments, reagents and any supply constraints. Stable supply would ease concern about GRAIL keeping its lab tests running; supply or servicing problems would put GRAIL's testing flow at risk because it depends on Illumina. Illumina's report alone cannot confirm deliveries to GRAIL.
AstraZeneca PLC earningsAZN
AstraZeneca's report can show the course of its oncology trials, where it uses GRAIL's tests and methylation technology.
Watch AstraZeneca's disclosed oncology-trial progress and whether more programs use biomarkers to select patients. Continuing or expanding programs would point to ongoing drug-company research demand and a pool of potential work for GRAIL's research services and tests; delays or fewer programs would narrow those opportunities. AstraZeneca's overall progress does not establish that GRAIL won work.
Personalis, Inc. earningsPSNL
Personalis's report can show drug-company demand for cancer biomarker research, work it competes with GRAIL to win.
Look at Personalis's biopharmaceutical research business, not its whole-genome sequencing work. Growth would show that drug companies are still paying for cancer-monitoring and biomarker research, while Personalis may also be winning more of that work; a contraction would point to fewer projects to pursue. Its revenue does not directly measure GRAIL's orders.
Guardant Health, Inc. earningsGH
Guardant Health's report will show how Shield blood-screening sales are developing as it and GRAIL's Galleri pursue demand for early cancer screening.
Focus on Guardant Health's reported Shield screening sales or test volume. Growth would show that blood-based multi-cancer screening is finding customers, while also showing GRAIL faces a rival winning adoption; weak growth would suggest commercial demand for this type of screening may still be limited, not that Galleri is doing better.
GRAIL, Inc. earningsThis company
Galleri screening brings in most of GRAIL's revenue, and this report will show whether test-volume growth can overcome price concessions and testing costs.
Read Galleri test volume alongside screening revenue and screening costs as a share of that revenue. More tests, revenue keeping pace and a falling cost share would show that volume is converting into revenue while unit costs improve; if tests rise but revenue lags and the cost share climbs, price concessions or costs such as sample reprocessing are eroding the gain.
